采用胜率法比较替代供者移植物抗宿主病无病、无复发生存率
在缺乏人类白细胞抗原(HLA)相合同胞或无关供者的患者中,最佳替代供者类型尚不明确。本研究采用GRFS的风险比(HR)和胜率法比较HLA不合无关供者、单倍体供者和脐带血移植,发现HLA不合无关供者移植结局相当或更优,脐带血移植胜率显著较低,提示需同时报告胜率与传统方法。
要点
- 单倍体供者与HLA不合无关供者相比,GRFS的HR为1.01,胜率为0.86,均无显著差异。
- 脐带血移植与HLA不合无关供者相比,GRFS的HR为1.14无显著差异,但胜率显著较低(0.80)。
- HLA不合无关供者移植在替代供者类型中显示相当或更优的结局。
核心结论
- HLA不合无关供者移植在替代供者类型中显示相当或更优的结局。
- 研究结果表明需同时报告胜率与传统方法以稳健评估终点。
研究设计与样本
- 比较HLA不合无关供者、单倍体供者和脐带血移植的研究,同时采用GRFS的风险比和胜率法分析。
主要发现
- 单倍体供者组与HLA不合无关供者组相比,GRFS的HR为1.01(95%CI 0.85-1.19,p=0.916),胜率为0.86(95%CI 0.72-1.02,p=0.081)。
- 脐带血移植与HLA不合无关供者相比,Cox比例风险模型显示GRFS的HR为1.14(95%CI 0.98-1.32,p=0.085),胜率显著较低为0.80(95%CI 0.68-0.93,p=0.004)。
- 脐带血移植与单倍体供者相比结局相似。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The optimal alternative donor type for patients lacking human leucocyte antigen (HLA)-matched related or unrelated donors remains unclear. In comparative studies evaluating donor types, graft-versus-host disease (GVHD)-free, relapse-free survival (GRFS) represents a well-established end-point but has limitations. The win ratio approach addresses these limitations by analysing multiple end-points with varying severities to account for the relative component priorities. We compared HLA-mismatched unrelated donors, haploidentical donors and cord blood using both the hazard ratio (HR) of GRFS and the win ratio related to GRFS. The haploidentical donor group had a similar HR of GRFS (HR: 1.01, 95% confidence interval [CI]: 0.85-1.19, p = 0.916) and win ratio (win ratio: 0.86, 95% CI: 0.72-1.02, p = 0.081) to HLA-mismatched unrelated donors. Cord blood transplantation showed similar GRFS compared to HLA-mismatched unrelated donors in the Cox proportional model (HR: 1.14, 95% CI: 0.98-1.32, p = 0.085), significantly lower win ratio (win ratio: 0.80, 95% CI: 0.68-0.93, p = 0.004) and similar outcomes to haploidentical donors. HLA-mismatched unrelated donor transplantation showed comparable to superior outcomes among alternative donor types. Our results indicate the need to present the win ratio alongside conventional methods to assess the end-point robustly.
引用
- Shimomura Y, Komukai S, Kitamura T, et al. A win ratio approach for comparing graft-versus-host disease-free, relapse-free survival among alternative donors. Br J Haematol. 2025. PMID: 40671206. doi:10.1111/bjh.70008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。